Oncology Institute Inc (TOI)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $512.91M
Last updated: Aug 03, 2026 at 7:34 PM ET
Oncology Institute Inc (TOI) Financials: Revenue, Profit and Cash Flow
Oncology Institute reported revenue of $502.73M for the fiscal year ended Dec 31, 2025, up 27.8% from the year before. That year, net income was -$60.61M with a net margin of -12.1%, operating cash flow was -$24.59M and free cash flow was -$27.79M. The quarter ended Sep 30, 2026 had revenue of $169.77M and net income of -$15.75M.
Revenue and Margins
The operating margin was -7.2% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $113.16M, a compound annual rate of 23.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $502.73M | +27.8% | 15.2% | -7.2% | -12.1% |
| Dec 2024 | $393.41M | +21.3% | 13.7% | -15.3% | -16.4% |
| Dec 2023 | $324.24M | +28.4% | 18.4% | -23.8% | -25.6% |
| Dec 2022 | $252.48M | +24.4% | 20.6% | -32.5% | 0.1% |
| Dec 2021 | $203.00M | +8.3% | 20.1% | -22.6% | -5.4% |
| Dec 2020 | $187.51M | +20.7% | 19.7% | -4.4% | -7.6% |
| Dec 2019 | $155.41M | +37.3% | 19.3% | -1.7% | -2.6% |
| Dec 2018 | $113.16M | N/A | 23.2% | 4.2% | 3.5% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $502.73M | $393.41M | $324.24M | $252.48M | $203.00M | $187.51M | $155.41M | $113.16M |
| Cost of revenue | $426.29M | $339.42M | $264.67M | $200.39M | $162.16M | $150.64M | $125.46M | $86.88M |
| Gross profit | $76.44M | $54.00M | $59.57M | $52.09M | $40.85M | $36.88M | $29.94M | $26.28M |
| Operating income | -$36.08M | -$60.12M | -$77.02M | -$81.95M | -$45.86M | -$8.20M | -$2.64M | $4.79M |
| Net income | -$60.61M | -$64.66M | -$83.07M | $152.00K | -$10.93M | -$14.32M | -$4.02M | $3.95M |
| EBITDA | -$21.01M | -$47.41M | -$67.05M | -$19.14M | -$14.21M | -$4.96M | $307.11K | $9.08M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.77M | $161.28M | $147.44M | $141.96M | $136.56M | $119.80M | $104.41M | $100.27M | $99.90M | $98.58M | $94.67M | $85.79M |
| Gross profit | N/A | N/A | $21.70M | $22.77M | $18.92M | $17.50M | $17.25M | $14.64M | $14.37M | $13.03M | $11.97M | $14.38M |
| Operating income | N/A | N/A | -$6.51M | -$6.91M | -$8.05M | -$11.21M | -$9.91M | -$11.93M | -$13.85M | -$16.36M | -$17.97M | -$15.29M |
| Net income | -$15.75M | -$9.79M | -$2.49M | -$7.51M | -$16.50M | -$17.01M | -$19.59M | -$13.18M | -$16.11M | -$15.48M | -$19.89M | -$18.75M |
Balance Sheet
As of Dec 2025, total debt of $127.72M exceeded cash and equivalents by $94.16M. Shareholder equity was negative, at -$15.72M, as total liabilities of $180.38M exceeded total assets of $164.66M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $164.66M | $172.72M | $209.24M | $261.67M | $203.44M | $65.69M | $50.00K | N/A |
| Current assets | $112.75M | $112.42M | $143.49M | $130.42M | $154.06M | $29.72M | $21.79M | N/A |
| Cash and equivalents | $33.56M | $49.67M | $33.49M | $14.01M | $115.17M | $6.00M | $25.00K | N/A |
| Total liabilities | $180.38M | $169.13M | $152.22M | $138.49M | $99.28M | $37.59M | $27.30K | N/A |
| Short-term debt | $50.32M | $31.12M | $20.79M | $14.87M | $15.74M | $18.01M | $800 | N/A |
| Long-term debt | $77.40M | $93.13M | $86.83M | $80.62M | $0 | $6.56M | N/A | N/A |
| Shareholder equity | -$15.72M | $3.59M | $57.02M | $123.17M | $104.16M | $28.10M | $22.70K | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $187.77M | $178.23M | $168.23M | $164.66M | $163.62M | $159.80M | $164.00M | $172.72M | $179.18M | $179.60M | $204.53M | $209.24M |
| Total liabilities | $225.13M | $203.15M | $184.51M | $180.38M | $175.89M | $168.78M | $158.93M | $169.13M | $163.70M | $150.40M | $163.24M | $152.22M |
| Cash and equivalents | $36.90M | $41.09M | $30.28M | $33.56M | $27.66M | $30.29M | $39.74M | $49.67M | $47.40M | $36.42M | $36.05M | $33.49M |
| Shareholder equity | -$37.35M | -$24.91M | -$16.29M | -$15.72M | -$12.27M | -$8.98M | $5.07M | $3.59M | $15.48M | $29.21M | $41.30M | $57.02M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.59M | -$26.54M | -$36.31M | -$61.76M | -$32.68M | $508.00K | $3.62M | $5.64M |
| Capital expenditures | $3.20M | $3.79M | $4.57M | $5.53M | $2.85M | $1.19M | $1.20M | $695.96K |
| Free cash flow | -$27.79M | -$30.33M | -$40.88M | -$67.28M | -$35.53M | -$686.00K | $2.41M | $4.95M |
| Dividends paid | N/A | N/A | $1 | N/A | N/A | $0 | N/A | $8.20M |
| Share repurchases | N/A | N/A | $1.02M | $9.00M | $0 | N/A | N/A | N/A |
| Investing cash flow | -$3.07M | $46.21M | $62.64M | -$131.61M | -$12.15M | -$8.84M | -$1.20M | $2.49M |
| Financing cash flow | $11.56M | -$3.49M | -$6.85M | $92.21M | $154.01M | $11.89M | -$1.81K | -$8.20M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.14M | $11.94M | -$2.21M | $3.23M | -$12.63M | -$10.20M | -$4.99M | $4.19M | $819.00K | -$15.66M | -$15.88M | -$3.89M |
| Capital expenditures | $1.26M | $908.00K | $1.04M | $1.06M | $604.00K | $1.21M | $328.00K | $1.75M | $402.00K | $1.83M | $610.00K | $861.00K |
| Free cash flow | $8.88M | $11.03M | -$3.26M | $2.17M | -$13.23M | -$11.41M | -$5.32M | $2.43M | $417.00K | -$17.49M | -$16.49M | -$4.75M |
Frequently Asked Questions About TOI
What is Oncology Institute's annual revenue?
Oncology Institute reported revenue of $502.73M for the fiscal year ended Dec 31, 2025.
How fast is Oncology Institute's revenue growing?
Revenue was up 27.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 25.8%.
Is Oncology Institute profitable?
No. Oncology Institute reported net income of -$60.61M for the fiscal year ended Dec 31, 2025, with a net margin of -12.1%.
How much free cash flow does TOI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.59M minus capital expenditures of $3.20M produced free cash flow of -$27.79M.
How much debt does Oncology Institute have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $77.40M, short-term debt of $50.32M and cash and equivalents of $33.56M.
TOI pages: Overview, Financials